Skip to content
Bored Studies
RecruitingPhase 3

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Pfizer · NCT07013474

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
70
Study start
July 14, 2025
Record last updated
October 14, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized at baseline with mild-to-moderate COVID-19.

Being studied: ibuzatrelvir; remdesivir; placebo for ibuzatrelvir; placebo for remdesivir

Conditions: COVID-19 Infection

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18 years of age or older at screening who are non-hospitalized or hospitalized with mild to moderate COVID-19
  • Confirmed SARS-CoV-2 infection as determined by RAT (or other locally approved test) collected within 2 days prior to randomization. Initial onset of symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified symptoms attributable to COVID-19 present on the day of randomization.
  • Severely immunocompromised due to:
  • Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy;
  • Active hematologic malignancy (eg, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia);
  • Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy;
  • Currently receiving or recently received B-cell depleting therapies (eg, rituximab), where the immunosuppressive effect is still ongoing.

Exclusion Criteria

  • Severe or critical COVID-19, or current need for supplemental oxygen.
  • Receiving dialysis or have current kidney failure (ie, eGFR consistently \<15 mL/min)
  • Active liver disease
  • History of hypersensitivity or other contraindication to any of the components of the study interventions, as determined by the investigator
  • Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
  • Life expectancy less than 30 days at study entry due to an underlying condition, in the judgement of the investigator.
  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Has received any other antiviral for the treatment of the current COVID-19 infection
  • Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).
  • Current or previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
  • Prior participation in this trial or any clinical trial of ibuzatrelvir.
  • Females who are pregnant, breastfeeding, or who are planning to become pregnant within the timeframe of the study.
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Recruiting US locations

+ 10 more on the official record.

Study contacts (from the official record)

  • Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults… (NCT07013474) | Bored Studies